Oncology
Radiopharmaceuticals Shine in Detecting, Treating Cancer
Radiopharmaceuticals are reshaping cancer care—experts discuss growth, costs, access, and managed care ...
APRIL 22, 2026
HOPA 2026: Updates in Small Cell Lung Cancer
Dr. Katie O’Reilly provides an update on treatments for both limited and extensive stages of small cell lung ...
APRIL 13, 2026
HOPA 2026: Best Practices for Clinical Trials Across the Enterprise
Drs. Elyse MacDonald and Jennifer Murphy provide implementation strategies and best practices to navigate a ...
APRIL 7, 2026
Happy National Oncology Pharmacists Day!
In honor of the inaugural National Oncology Pharmacists Day, PPN caught up with some HOPA attendees to ask how does ...
APRIL 3, 2026
Oncology Pharmacist Day Aims to Raise Profession’s Profile
Oncology pharmacists gain national recognition with Oncology Pharmacist Day, honoring their expanding role in ...
APRIL 2, 2026
Patients, Providers Reap Benefits Of Pharmacist-Managed Oral Chemo
Oncology pharmacists at Fred Hutchinson Cancer Center improve oral chemotherapy safety, adherence, and efficiency ...
APRIL 1, 2026
HOPA 2026: 340B Drug Pricing Program Updates
Dr. Anthony Trovato provides an overview of the recent and ongoing updates to the 340B Drug Pricing Program, what ...
MARCH 31, 2026
A Synergy of CAR-T Hematotoxicity Scoring Tools
Cytopenia prediction strategies using CAR-HEMATOTOX and KyoTox show phase-specific strengths that aid precision ...
MARCH 30, 2026
HOPA 2026: Role of GLP-1s in Oncology
Drs. Colleen McCabe and Lindsay Mundy discuss both the potential risks and benefits of GLP-1s for patients actively ...
MARCH 27, 2026
Survey Shows Wide Variation, Significant Gaps in Oncology Pharmacy Residency Leadership
Cancer pharmacology programs reveal leadership strain and uneven support for preceptors guiding advanced clinical ...
MARCH 26, 2026
HOPA 2026: What's New in Gastric and Esophageal Cancers
Jeremy Pappacena, PharmD, BCOP, provides an update on how treatment and management of gastric and esophageal ...
MARCH 26, 2026
Targeted Approach Expands Oral Options for Breast Cancer
Innovations in precision medicine are redefining treatment for hormone HR-positive, HER2-negative breast cancer and ...
MARCH 12, 2026
